[Current insulin therapy. Treatment with new short-acting and retard insulin analogs].
Intensified insulin therapy of type I diabetics can now be rendered more patient-friendly through the use of rapid-action insulin. Thus, for example, the rapid absorption of the monomeric lispro insulin (Humalog) out of the subcutaneous fatty tissue obviates the need to observe a delay between injection and meal, and the changed kinetics of action reduce the danger of postprandial episodes of hypoglycemia. In addition to practice-relevant hints on the use of these new short-acting insulins in intensified insulin therapy, this short article reviews the current state of the development of a new long-acting insulin that is shortly to be tested in an international multi-center phase III study.
Matthaei
S
S
Medizinische Kernklinik und Poliklinik, Universitäts-Krankenhaus Eppendort, Hamburg.
Hamann
A
A
D001786:Blood Glucose / Q000378:metabolism; D003692:Delayed-Action Preparations; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007328:Insulin / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood; D013329:Structure-Activity Relationship
D001786:Blood Glucose; D003692:Delayed-Action Preparations; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin
Aktuelle Insulintherapie. Behandlung mit neuen kurz- und langwirkenden Insulinanaloga.